EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dysregulated BARD1 Contributes to Paclitaxel Resistance in Ovarian Cancer via Up-regulating CYP2C8

Li Zhang, Zixuan Pan, Liqin Zhang, Hua Liu, Zonglan Li, Shuo Feng

Folia Biologica · 2025

DOI: 10.14712/fb2025071030109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Folia Biologica, 2025. Verfasst von Li Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Gynecology Department 1, Affiliated Hospital of Shandong Second Medical University, Weifang, China. Hauptthemen laut MEDLINE: Paclitaxel, Ovarian Neoplasms, Tumor Suppressor Proteins, Drug Resistance, Neoplasm. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Weifang Medical University, Weifang University of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer remains one of the most lethal gynaecological malignancies, with paclitaxel resistance being a major therapeutic challenge that limits treatment efficacy and patient survival. We found that although the BARD1 level was not signi­ficantly altered in patients with ovarian cancer (OC), patients with higher BARD1 levels had increased survival time, suggesting that the down-regulation of BARD1 may be related to the paclitaxel sensitivity. Through examining the expression of BARD1 in tumour samples from paclitaxel responders and non-responders, we observed that the BARD1 level was significantly reduced in non-responders. CYP2C8 was up-regulated in non-responders. Also, the BARD1 level was negatively correlated with the level of CYP2C8. BARD1 over-expression in OC cells could repress the CYP2C8 expression, while knockdown of BARD1 could up-regulate CYP2C8 expression, which could be rescued by H2A-Ub. Results from gain and loss of functional experiments indicated that BARD1 functions as a tumour suppressor during paclitaxel treatment, and BARD1 down-regulation increased the IC50 of paclitaxel from 2.46 nM to 5.33 nM in SK-OV-3 cells and from 3.11 nM to 7.51 nM in CaoV-3 cells. We are the first to demonstrate that the down-regulation of BARD1 contributes to paclitaxel resistance via up-regulating CYP2C8 in patients with OC, which provides a potent target for clinical OC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelOvarian NeoplasmsTumor Suppressor ProteinsDrug Resistance, NeoplasmCytochrome P-450 CYP2C8Up-RegulationUbiquitin-Protein LigasesHumansFemaleCell Line, TumorGene Expression Regulation, NeoplasticMiddle Aged

Stichwörter der Autor:innen

BARD1CYP2C8ovarian cancerpaclitaxelresistance

Substanzen

PaclitaxelTumor Suppressor ProteinsCytochrome P-450 CYP2C8BARD1 protein, humanCYP2C8 protein, humanUbiquitin-Protein Ligases

Autor:innen und Institutionen

  • Gynecology Department 1, Affiliated Hospital of Shandong Second Medical University, Weifang, China.
  • Gynecology Department 1, Affiliated Hospital of Shandong Second Medical University, Weifang, China. shunfengvictory@126.com.
  • Gynecology Department, Affiliated Hospital of Shandong Second Medical University, Fuyanshan District, Weifang, China.

Förderung

  • Weifang Medical University
  • Weifang University of Science and Technology

Zitieren

APA

Zhang, L., Pan, Z., Zhang, L., Liu, H., Li, Z., & Feng, S. (2025). Dysregulated BARD1 Contributes to Paclitaxel Resistance in Ovarian Cancer via Up-regulating CYP2C8. Folia Biologica. https://doi.org/10.14712/fb2025071030109

Vancouver

Zhang L, Pan Z, Zhang L, Liu H, Li Z, Feng S. Dysregulated BARD1 Contributes to Paclitaxel Resistance in Ovarian Cancer via Up-regulating CYP2C8. Folia Biologica. 2025. doi:10.14712/fb2025071030109

BibTeX
@article{Zhang2025,
  author = {Zhang, Li and Pan, Zixuan and Zhang, Liqin and Liu, Hua and Li, Zonglan and Feng, Shuo},
  title = {Dysregulated BARD1 Contributes to Paclitaxel Resistance in Ovarian Cancer via Up-regulating CYP2C8},
  journal = {Folia Biologica},
  year = {2025},
  doi = {10.14712/fb2025071030109}
}
Kostenlos starten →